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ABSTRACT 
Objective: In the present investigation, fast dissolving tablets of cefpodoxime proxetil were formulated using superdisintegrants to impart fast 
disintegration.  
Methods: In the current study, 12 formulations of fast dissolving tablets of cefpodoxime proxetil were formulated using two different approaches 
viz., direct compression and sublimation. Three different superdisintegrants viz., croscarmellose sodium, sodium starch glycolate, and crospovidone 
were used in a different concentration in all the respective formulations. The final powder blend was subjected for the pre-compression evaluation 
and all the formulations were evaluated for post-compression parameters. Stability studies were also evaluated for the best formulations as per ICH 
guidelines. Finally, results were statistically analyzed by the application of one way ANOVA test and t-test.  
Results: Among all the formulations of different approaches, formulation cefpodoxime proxetil 4 (CP4) containing 6% crospovidone as a super 
disintegrant was showed the best results. In vitro dissolution data revealed that formulation CP4 prepared by direct compression method showed 
99.387±0.270% drug release within 15 min whereas the percentage release by formulation prepared by using sublimation showed 83.927±0.735% 
release. The optimized formulation was further subjected to comparative in vitro study with two marketed formulation of different brands.  
Conclusion: All the data of all formulations is shows that direct compression approach is the best approach for developing the fast dissolving 
tablets to enhance the onset of action and bioavailability. 
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INTRODUCTION 
The most suitable and widely acceptable delivery system for drug 
administration is the oral drug delivery system because of its self-
administration; compactness and easy manufacturing [1]. More than 
75% of drugs are given in orally. Oral drug delivery system is 
becoming important day by day due to its fine characteristics; no 
invasion, no pain, easy to handle and patient compliance [2]. Due to 
its great importance, it also left some of the drawbacks, in which the 
major drawback is dysphagia [3]. Pediatrics and geriatrics patients 
suffer a lot from the dysphagia (difficulty in swallowing) which leads 
to poor patient compliance [4]. Therefore, to improvise such issues 
novel drug delivery system is come in existence called fast dissolving 
tablets (FDTs).  
The demands of the development of FDTs are increased enormously 
as it has a great impact on patient compliance. Fast disintegrating 
tablets (FDTs) are gaining more popularity because drug gets 
dissolved or easily disintegrated in the mouth within a sec without 
the need of water [5]. 
Nowadays, fast dissolving tablets are very important to increase the 
bioavailability of the drug and onset of action in comparison with 
conventional tablets which have low bioavailability, low solubility 
and the large onset of action. Basic considerations of FDTs are to 
improve the aqueous solubility, permeability, mechanical strength 
etc. therefore drugs which have low aqueous solubility and low 
permeability (Class III drugs of BCS System) are considered 
important [6, 7]. 
Cefpodoxime proxetil (CP) is a broad spectrum third-generation 
cephalosporin, which shows effective antibacterial activity against 
both gram-positive and gram-negative bacteria. Cefpodoxime proxetil 
having the low aqueous solubility and also having the low oral 
bioavailability up to 50% that may have a negative impact on its sub-
therapeutic plasma drug levels leading to therapeutic failure [8, 9]. 
Consequently, to improve the aqueous solubility and bioavailability 
of cefpodoxime proxetil, FDTs of cefpodoxime proxetil will be in 
consideration. Therefore, it is hypothesized that fast dissolving 
tablets of cefpodoxime proxetil will provide enhanced bioavailability 
and better patient compliance. 
In the present study fast dissolving tablets of cefpodoxime proxetil 
was achieved by using two different methods viz., direct 
compression and sublimation method in-order to improve the 
disintegration time and dissolution rate which may further improve 
bioavailability and faster onset of action of drug. 
MATERIALS AND METHODS 
Cefpodoxime proxetil was obtained as gift sample from INOVA 
CAPTAB UNIT-II Baddi, HP, India, sodium starch glycolate, 
microcrystalline cellulose, croscarmellose sodium were obtained as 
a gift sample from Maple Biotech Pvt. Ltd. Pune, India. All other 
ingredients and chemicals used were of analytical grade. 
Preformulation studies  
All the preformulation parameters were carried out effectively. 
Differential scanning calorimetry 
Differential scanning calorimetry (DSC) analysis was performed 
using Perkin-Elmer Series 7 DSC on 2 to 8 mg samples pure 
cefpodoxime proxetil [10]. 
Compatibility studies 
A perfectly dried sample of the pure drug (with excipients) was 
mixed with dried potassium bromide (KBr) powder. The mixture 
was then subjected to KBr press to obtain the mixture pellet. The 
pressure for preparing the palate was between 10000 to 12000 psi. 
The prepared drug pellet was scanned between 4000 to 400 cm-1 at 
a resolution of 4 cm-1. The spectrum was recorded and interpreted 
for the confirmation of the drug purity [11, 12]. 
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Determination of absorption maxima (max) 
Known concentrations of cefpodoxime proxetil were prepared in 
different solvents viz., glycine buffer of pH 3.0. Concentrations were 
then scanned in UV spectrum mode in the range of 400-200 nm 
against similarly treated blank [13]. 
Calibration curve  
Accurately weighed, 100 mg of cefpodoxime proxetil was dissolved 
in 50 ml of glycine buffer pH 3.0 in 100 ml of the pre-calibrated 
volumetric flask. The solution was shaken for few minutes until a 
clear solution was obtained and volume was makeup with methanol 
which gives a standard solution of 1000 g/ml. Different dilutions of 
known concentration were prepared from the standard solution 
ranging between 20-32 g/ml. Absorption was measured at 257 nm 
using glycine buffer pH 3.0 as blank. 
Determination of qualitative solubility of cefpodoxime proxetil 
in different solvents 
The solubility of cefpodoxime proxetil was determined in various 
solvents viz., methanol, water, phosphate buffer pH 6.8, and glycine 
buffer pH 3.0, 0.1N HCl. Solubility was done by Higuchi conner 
method [13]. Active drug was added in different solvents in 10 ml of 
the volumetric flask. All volumetric flasks were placed in digital 
water bath shaker for 72 h continuous shaking at ambient 
temperature. After that, the solution was filtered using Whatman 
filter paper (No. 42). The filtrate solution was then further diluted 
and absorption was measured by UV-VIS spectrophotometer against 
similarly treated blank. 
Preparation of fast dissolving tablets (FDTs) 
FDTs were prepared by two different techniques viz; direct 
compression and sublimation technique using different 
superdisintegrants at a different level of concentrations. The entire 
ingredients were weighed carefully and were sieved through sieve 
no. 60 [14, 15]. 
The blend was mixed thoroughly and was directly subjected to 
compression into 200 mg tablets using tablet punching machine. 
Then compressed tablets of the sublimation technique were allowed 
to sublime by placing them in a hot air oven for 6 h at a temperature 
of 60±1 °C [16, 17]. All the prepared formulations were then 
subjected for further evaluations. 
 
Table 1: Composition of fast dissolving tablets CP1-C12 
Ingredients (mg) Direct compression method (CP1-CP6) Sublimation method (CP7-CP12) 
CP1 CP2 CP3 CP4 CP5 CP6 CP7 CP8 CP9 CP 10 CP 11 CP 12 
CP 50 50 50 50 50 50 50 50 50 50 50 50 
SSG     8 12 8 12     
CCS 8 12       8 12   
Crospovidone   8 12       8 12 
Camphor       6 6 6 6 6 6 
Mg. stearate 6 6 6 6 6 6 6 6 6 6 6 6 
Talc 6 6 6 6 6 6 6 6 6 6 6 6 
MCC 124 120 124 120 124 120 119 115 119 115 119 115 
SLS 1 1 1 1 1 1 1 1 1 1 1 1 
Aspartame 4 4 4 4 4 4 4 4 4 4 4 4 
Menthol 1 1 1 1 1 1       
Net weight (mg) 200 200 200 200 200 200 200 200 200 200 200 200 
*CP = cefpodoxime proxetil, SSG = sodium starch glycolate, CCS = cross caramellose sodium, MCC = micro crystalline sodium, SLS = sodium lauryl sodium  
 
Evaluation of tablets 
Pre-compression evaluation 
Pre-compression method of powder blend was evaluated effectively 
which includes bulk density, tapped density, hauser's ratio, carr’s 
index and angle of repose (θ) [18-21]. 
Post-compression evaluation 
All the prepared formulations were subjected to post-compression 
evaluations. 
Hardness  
The hardness of the tablets was evaluated by monsanto hardness 
tester. 6 tablets of each batch were taken randomly for hardness and 
average hardness was calculated [22]. 
Thickness  
20 tablets of each batch were selected randomly and the thickness 
was determined by digital vernier calliper. Average of the thickness 
was then calculated [23]. 
Uniformity of the weights 
Randomly, 20 tablets were taken from each batch and accurately 
weighed individually by digital weighing balance and the average 
weight of each batches tablets were calculated. Weight variation of 
the individual tablet was calculated and compared with the standard 
limits as per Indian Pharmacopoeia (IP) [24]. 
Friability 
Friability of the tablets was determined by using the friability test 
apparatus. Accurately pre-weighed 20 tablets were taken and placed 
onto the digital friabilator [25]. The friabilator was rotated to 100 
revolutions for 4 min. The loss of weight of the tablets was measured 
and friability was calculated. 
Uniformity of the drug content 
Six tablets of each batch were taken and crushed to form a fine powder 
and powder was weighed equivalent to 50 mg of the drug. A weighed 
amount of powder was dissolved in small amount glycine buffer pH 
3.0 which was freshly prepared into the 100 ml volumetric flask. Make 
up the volume after sonication was done for 25 min. The mixture was 
then filtered by using whatman filter paper (No. 42). 1 ml of the 
solution was taken and make up the volume up to the mark (100 ml). 
The final solution was analyzed in UV-VIS spectrophotometer at 257 
nm wavelength against similarly treated blank [26, 27]. 
In vitro disintegration time 
Six tablets were taken from all formulations and maintaining the 
water temperature at 37.0±0.5 °C. Time taken for complete the 
disintegration of tablets was recorded by stopwatch. For accuracy, 
an average of six tablets was taken [28]. 
Wetting time 
10 cm diameter five tissue papers were placed in a dry petri plate. 2 
ml of amaranth dye solution was added to the petri plate along with 
10 ml of simulated saliva solution. Tablets were put on the tissue 
paper and the time for complete wetting was measured by a 
stopwatch. Average three tablets of each batch were measured [29]. 
Water absorption ratio 
10 cm diameter five tissue papers were placed in a dry Petri plate. 2 ml 
of amaranth dye solution was added to the Petri plate along with 10 ml 
of simulated saliva solution. Tablets which were pre-weighed were put 
on the paper. When the tablets were wet in all sides, 
re-weighed and water absorption ratio was calculated [30
In vitro dissolution studies 
USP Type-II (paddle type) dissolution apparatus
vitro dissolution. Three tablets of each batch were used for 
determination of dissolution studies. Glycine buffer pH 3.0 (900 ml) 
was used as dissolution media which was maintained at 37.0
and speed of the paddle were adjusted at 75 rpm. 10 ml sample was 
withdrawn at the different time of interval and diluted adequately. 
All samples were analyzed at 257 nm wavelength in UV
spectrophotometer using similarly treated blank. From the raw 
dissolution data, the total amount of drug release profile was 
calculated at a different interval of time [31]. The kinetic studies for 
all formulations were also done. Further, the optimized formulation 
was subjected to comparative in vitro studies with the 
formulation of two different brands. 
Statistical analysis 
Statistical analysis of selected formulation and marketed 
formulations was done using graph pad prism 7.0 software. 
Statistical analysis is important to check the formulation that the 
selected formulation is significant or not significant
  
Fig. 2: Cefpodoxime proxetil calibration curve in glycine buffer pH 3.0
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Short-term stability studies of opt
In the present study, selected batch in 
placed in a stability chamber for stability studies at 40.0
75.0±5.0 % RH for 3 mo. Samples were collected after 
and evaluated for physical appearance, disintegration time wetting 
time, drug content and in vitro dissolution [3
RESULTS AND DISCUSSION 
Pre-formulation parameters 
Cefpodoxime proxetil was observed for organoleptic properties like 
physical appearance, odor, and melting point. The drug was 
identified with the help of UV and FTIR and exhibited absorption 
maxima at 257 nm when methanol was used as a 
mentioned in the literature (fig. 
found to be 24-32µg/ml and the standard curve has shown R
of 0.996 with the euqtion of linearity as y=0.11x+0.002 as shown in 
fig. 2. 
Differential scanning calorimeter shows endothermic fusion peak at 
110.45 C, which was corresponding to the melting point of 
cefpodoxime proxetil (fig. 3). 





aluminum foil pack was 
±2.0 °C/ 
3 mo interval 
3]. 
solvent as 






Solubility studies of the drug was performed and it was found that 
drug was slightly soluble in water with solubility of 0.90
 
Table 2: Solubility studies of cefp
S. No. Solvent used 
1 Methanol 
2 Ethanol 
3 Water (pH 7.0) 
4 Phosphate buffer pH 6.8 
5 Glycine buffer pH 3.0 
6 0.1N HCl 
 
Compatibilities studies  
Compatibility studies of the powered pure drug 
different excipients like crospovidone, sodium starch glycolate and 
 
Table 3: Comparison of the peak of functional groups observed in FTIR spectra of compatibility studies
IR spectra The peak
OH from H
amide NH stretch





*CCS = cross caramellose sodium, SSG = sodium starch glycolate 
 













*mean±SD, n = 3, SD = standard deviation 
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Fig. 3: DSC thermogram of cefpodoxime proxetil 
±0.021 
mg/ml whereas drug was highly soluble in methanol with solubility 
of 735.56±0.104 mg/ml 
odoxime proxetil in different solvents
Solubility (mg/ml) Solubility profile
735.56±0.021 Freely soluble
198.23±0.002 Freely soluble




were done with 
cross caramellose sodium. All spectrums were subjected 
interpretation with a comparison
spectra’s. Comparisons of the peak of functional groups ob
FTIR spectra of compatibility studies 







 2985.94, 2939.64 1760.00 1674
-3319.63 2985.94, 2939.64 1761.08 1674.28
-3506.74 2985.94, 2940.61 1758.19 1674.28
-3506.74 2985.94, 2940.61 1758.19 1673.32
-3525.06 2985.94, 2939.64 1761.08 1674.28
 
Table 4: Evaluation of powder blend 
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All formulations were evaluated effectively for 
evaluations. Data is represented in table 4. 
Post-compression evaluations 
Post-compression evaluations of all formulations were carried out 
successfully and data are tabulated table 5 and
[27]. 
  
Table 5: Post compression evaluations of prepared formulations CP1













*mean±SD, n = 3, SD = standard deviation, n = number of treatments
 
Table 6: Post compression evaluations of prepared formulations CP1













*mean±SD, n = 3, SD = standard deviation  
 
Fig. 4: Comparative 
Hence, the release profile revealed that tablets containing super 
disintegrants were better in term of drug release, further 
crospovidone resulting in faster drug release 99.387
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pre-compression 
 table 6 respectively 
In vitro dissolution studies were conducted for all the formulations via 
USP type-II dissolution apparatus, using glycine buffer pH 3.0 as a 
dissolution medium. It was observed that more than 90 % drug was 
released within 15 min in direct compression method formula
(CP1-CP6). Tablets formulated by the 
more than 80 % of the drug release within 1
that containing 6 % of crospovidone revealed maximum drug release 
profile up to 99.387±0.270 % within 1
CP12 showed 83.927±0.735 % drug release (fig. 
-CP12




























in vitro drug release profile of all formulations (CP1-CP12)
 
±0.270 % 
within 15 min, when compared with other super disintegrants [28].
The Formulation CP4 prepared by direct compression method also 




sublimation method showed 
5 min. Formulation CP4 
5 min, whereas formulation 
4). 
 






























prepared by sublimation. Therefore, CP4 formulation 
as best formulation and further subjected for comparative 
drug release with two marketed formulation of different brands.
  
Fig. 5: Comparative 
 
The in vitro release data were subjected to various mathematical 
release models viz., zero order, first order, Higuchi and Pappas and 
best-fit model were decided by the highest R
 
Table 7: Curve Fitting Data of the release rate profile of formulations CP1 to CP12
Formulation code Models 














Statistical analysis of selected formulation and marketed 
formulations were calculated by graph pad prism 7.0. Applying, one 
way ANOVA, it was found that there is no significant difference in all 
twelve formulations. Using t-test for comparison of the 
formulation with marketed formulations, formulation CP4 and 
MKT1 showed that there was no significant difference.
Thus, above studies indicate that formulation CP4, 
having an almost similar profile, but CP4 will provide 










Drug content (%) 
Disintegration Time (sec) 
Wetting Time (sec) 
*mean±SD, n = 3, SD = standard deviation, CDR = cumulative drug release
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marketed formulations showed 
% drug release in 15 min (Figure5)
tabulated in table 10 and fig. 5 respectively.
in vitro drug release profile of CP4, MKT1, and MKT2
2 value. On the basis 
of maximum regression value, Higuchi Model for drug release 
kinetics was found to be the best fit model for most of the 
formulations (table 7). 
1st Order (R2) Higuchi (R2) Pappas (R
0.821 0.994 0.914 
0.929 0.994 0.886 
0.950 0.940 0.843 
0.899 0.926 0.832 
0.934 0.993 0.868 
0.927 0.961 0.849 
0.621 0.995 0.898 
0.621 0.995 0.885 
0.584 0.995 0.893 
0.967 0.987 0.899 
0.960 0.989 0.901 
0.863 0.989 0.890 
selected 
 
MKT1, and MKT2 is 
improved onset 
 
Short-term stability study of the 
A sample withdrew after three 
change in in vitro drug release profile. All the data showed the 
good similarity of dissolution profile before and after stability 
studies (table 8). Results of the stability study had shown no 
remarkable change in the release profile of the cefpodoxime 
proxetil FDTs after the stability
formulation CP4 was found to be stable and complies with 
pharmacopeial standards. 
Short-term stability study of optimized formulation (CP4) 













88.907±0.566 % and 92.627±0.719 



















months shown no more drastic 
. Stability study of selected 
3 mo) 
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CONCLUSION 
Fast dissolving tablets were prepared in two different approaches to 
direct compression and sublimation. Pre-formulations parameters 
like the physical characterization of the drug were evaluated. All the 
formulations were passed the pre-compression and post-
compression parameters. Formulation CP4 that contained 6 % of 
crospovidone showed the fastest drug release of 99.387±0.270 % 
within 15 min which was the optimized formulation. Thus, it was 
concluded that fast dissolving tablets of cefpodoxime proxetil can be 
successfully prepared using direct compression technique and it will 
enhance the drug dissolution which will further increase absorption 
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